Cantor Fitzgerald Issues Pessimistic Forecast for Artiva Biotherapeutics (NASDAQ:ARTV) Stock Price

Artiva Biotherapeutics (NASDAQ:ARTV) had its price target cut by analysts at Cantor Fitzgerald from $23.00 to $20.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 421.51% from the stock’s current price.

A number of other equities research analysts have also weighed in on ARTV. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday. Finally, HC Wainwright initiated coverage on Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $20.40.

Artiva Biotherapeutics Stock Performance

ARTV stock traded down $0.08 during midday trading on Tuesday, reaching $3.84. The company’s stock had a trading volume of 23,414 shares, compared to its average volume of 113,040. Artiva Biotherapeutics has a 1 year low of $3.37 and a 1 year high of $17.31. The stock has a fifty day simple moving average of $4.97 and a two-hundred day simple moving average of $9.43.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth $42,000. Charles Schwab Investment Management Inc. grew its position in Artiva Biotherapeutics by 8.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock worth $439,000 after purchasing an additional 3,233 shares during the last quarter. Wells Fargo & Company MN increased its stake in Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after purchasing an additional 3,361 shares in the last quarter. Northern Trust Corp increased its stake in Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock valued at $1,180,000 after purchasing an additional 4,335 shares in the last quarter. Finally, Barclays PLC raised its holdings in shares of Artiva Biotherapeutics by 23.2% in the fourth quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after buying an additional 4,545 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.